# OnCo record nk-cell-recognition (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/nk-cell-recognition/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "nk-cell-recognition" ;
  schema:name "NK-cell recognition: missing self & stress ligands"@en ;
  schema:description "Natural killer cells patrol for cells that have lost their identity papers (MHC-I) or that display stress flags. Cancers that hide from T cells by dropping MHC-I become visible to NK cells, unless they also shed the stress flags, wrap themselves in a second inhibitory badge (HLA-E), or soak the neighbourhood in TGF-β."@en ;
  schema:url <https://onco.cc/pathways/nk-cell-recognition/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Natural_killer_cell> ;
  schema:citation <https://doi.org/10.1038/nrc.2015.5> ;
  onco:tag "mechanism", "mechanics-atlas" ;
  onco:technologies <https://onco.cc/technologies/car-nk-macrophage/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/cytokine-therapy/>, <https://onco.cc/technologies/allogeneic-cell-therapy/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/tigit/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd38/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/margetuximab/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/nogapendekin-alfa/>, <https://onco.cc/drugs/tiragolumab/> ;
  onco:pathways <https://onco.cc/pathways/antigen-presentation-immunoediting/>, <https://onco.cc/pathways/extrinsic-apoptosis-death-receptors/>, <https://onco.cc/pathways/tgf-beta/>, <https://onco.cc/pathways/intravasation-ctc-survival/>, <https://onco.cc/pathways/tumor-dormancy/> ;
  onco:terms <https://onco.cc/terms/adcc/>, <https://onco.cc/terms/fc-effector/>, <https://onco.cc/terms/bcg-unresponsive/>, <https://onco.cc/terms/avoiding-immune-destruction/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-morvan-nat-rev-cancer/> .